185 related articles for article (PubMed ID: 19718438)
1. Glioblastoma formation from cell population depleted of Prominin1-expressing cells.
Nishide K; Nakatani Y; Kiyonari H; Kondo T
PLoS One; 2009 Aug; 4(8):e6869. PubMed ID: 19718438
[TBL] [Abstract][Full Text] [Related]
2. Prominin 1/CD133 endothelium sustains growth of proneural glioma.
Ding BS; James D; Iyer R; Falciatori I; Hambardzumyan D; Wang S; Butler JM; Rabbany SY; Hormigo A
PLoS One; 2013; 8(4):e62150. PubMed ID: 23637986
[TBL] [Abstract][Full Text] [Related]
3. Prominin-1 (CD133) defines both stem and non-stem cell populations in CNS development and gliomas.
Holmberg Olausson K; Maire CL; Haidar S; Ling J; Learner E; Nistér M; Ligon KL
PLoS One; 2014; 9(9):e106694. PubMed ID: 25184684
[TBL] [Abstract][Full Text] [Related]
4. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors.
Liu Q; Nguyen DH; Dong Q; Shitaku P; Chung K; Liu OY; Tso JL; Liu JY; Konkankit V; Cloughesy TF; Mischel PS; Lane TF; Liau LM; Nelson SF; Tso CL
J Neurooncol; 2009 Aug; 94(1):1-19. PubMed ID: 19468690
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of ex-vivo CD133+ GBM cells revealed a common invasive and angiogenic profile but different proliferative signatures among high grade gliomas.
Garcia JL; Perez-Caro M; Gomez-Moreta JA; Gonzalez F; Ortiz J; Blanco O; Sancho M; Hernandez-Rivas JM; Gonzalez-Sarmiento R; Sanchez-Martin M
BMC Cancer; 2010 Aug; 10():454. PubMed ID: 20735813
[TBL] [Abstract][Full Text] [Related]
6. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
Venugopal C; Hallett R; Vora P; Manoranjan B; Mahendram S; Qazi MA; McFarlane N; Subapanditha M; Nolte SM; Singh M; Bakhshinyan D; Garg N; Vijayakumar T; Lach B; Provias JP; Reddy K; Murty NK; Doble BW; Bhatia M; Hassell JA; Singh SK
Clin Cancer Res; 2015 Dec; 21(23):5324-37. PubMed ID: 26152745
[TBL] [Abstract][Full Text] [Related]
7. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
Choy W; Nagasawa DT; Trang A; Thill K; Spasic M; Yang I
Neurosurg Clin N Am; 2012 Jul; 23(3):391-405. PubMed ID: 22748652
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous phenotype of human glioblastoma: in vitro study.
Denysenko T; Gennero L; Juenemann C; Morra I; Masperi P; Ceroni V; Pragliola A; Ponzetto A; Melcarne A
Cell Biochem Funct; 2014 Mar; 32(2):164-76. PubMed ID: 23836332
[TBL] [Abstract][Full Text] [Related]
9. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma.
Chen R; Nishimura MC; Bumbaca SM; Kharbanda S; Forrest WF; Kasman IM; Greve JM; Soriano RH; Gilmour LL; Rivers CS; Modrusan Z; Nacu S; Guerrero S; Edgar KA; Wallin JJ; Lamszus K; Westphal M; Heim S; James CD; VandenBerg SR; Costello JF; Moorefield S; Cowdrey CJ; Prados M; Phillips HS
Cancer Cell; 2010 Apr; 17(4):362-75. PubMed ID: 20385361
[TBL] [Abstract][Full Text] [Related]
10. Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57.
Zhu X; Prasad S; Gaedicke S; Hettich M; Firat E; Niedermann G
Oncotarget; 2015 Jan; 6(1):171-84. PubMed ID: 25426558
[TBL] [Abstract][Full Text] [Related]
11. Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
Brown DV; Daniel PM; D'Abaco GM; Gogos A; Ng W; Morokoff AP; Mantamadiotis T
Oncotarget; 2015 Mar; 6(8):6267-80. PubMed ID: 25749043
[TBL] [Abstract][Full Text] [Related]
12. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells.
Wang J; Sakariassen PØ; Tsinkalovsky O; Immervoll H; Bøe SO; Svendsen A; Prestegarden L; Røsland G; Thorsen F; Stuhr L; Molven A; Bjerkvig R; Enger PØ
Int J Cancer; 2008 Feb; 122(4):761-8. PubMed ID: 17955491
[TBL] [Abstract][Full Text] [Related]
13. CD133 is essential for glioblastoma stem cell maintenance.
Brescia P; Ortensi B; Fornasari L; Levi D; Broggi G; Pelicci G
Stem Cells; 2013 May; 31(5):857-69. PubMed ID: 23307586
[TBL] [Abstract][Full Text] [Related]
14. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression.
Gambelli F; Sasdelli F; Manini I; Gambarana C; Oliveri G; Miracco C; Sorrentino V
Cell Biol Int; 2012 Jan; 36(1):29-38. PubMed ID: 21916848
[TBL] [Abstract][Full Text] [Related]
15. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
Beier D; Hau P; Proescholdt M; Lohmeier A; Wischhusen J; Oefner PJ; Aigner L; Brawanski A; Bogdahn U; Beier CP
Cancer Res; 2007 May; 67(9):4010-5. PubMed ID: 17483311
[TBL] [Abstract][Full Text] [Related]
16. Comparative genomics on PROM1 gene encoding stem cell marker CD133.
Katoh Y; Katoh M
Int J Mol Med; 2007 Jun; 19(6):967-70. PubMed ID: 17487431
[TBL] [Abstract][Full Text] [Related]
17. Prominin-1/CD133 marks stem cells and early progenitors in mouse small intestine.
Snippert HJ; van Es JH; van den Born M; Begthel H; Stange DE; Barker N; Clevers H
Gastroenterology; 2009 Jun; 136(7):2187-2194.e1. PubMed ID: 19324043
[TBL] [Abstract][Full Text] [Related]
18. Investigating the link between molecular subtypes of glioblastoma, epithelial-mesenchymal transition, and CD133 cell surface protein.
Zarkoob H; Taube JH; Singh SK; Mani SA; Kohandel M
PLoS One; 2013; 8(5):e64169. PubMed ID: 23734191
[TBL] [Abstract][Full Text] [Related]
19. Girdin maintains the stemness of glioblastoma stem cells.
Natsume A; Kato T; Kinjo S; Enomoto A; Toda H; Shimato S; Ohka F; Motomura K; Kondo Y; Miyata T; Takahashi M; Wakabayashi T
Oncogene; 2012 May; 31(22):2715-24. PubMed ID: 22020337
[TBL] [Abstract][Full Text] [Related]
20. Glioma cell populations grouped by different cell type markers drive brain tumor growth.
Prestegarden L; Svendsen A; Wang J; Sleire L; Skaftnesmo KO; Bjerkvig R; Yan T; Askland L; Persson A; Sakariassen PØ; Enger PØ
Cancer Res; 2010 Jun; 70(11):4274-9. PubMed ID: 20460538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
